Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-Derived Xenograft Models of Gastrointestinal Stromal Tumors

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-1858
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Application of Highly Immunocompromised Mice for the Establishment of Patient-Derived Xenograft (PDX) Models

Cells
2019English

Prognostic Value of KIT/PDGFRA Mutations in Gastrointestinal Stromal Tumors: A Meta-Analysis

World Journal of Surgical Oncology
SurgeryOncology
2014English

Targeting HER2 in Patient-Derived Xenograft Ovarian Cancer Models Sensitizes Tumors to Chemotherapy

Molecular Oncology
Cancer ResearchMedicineOncologyGeneticsMolecular Medicine
2018English

Multiregion Genomic Analysis of Serially Transplanted Patient-Derived Xenograft Tumors

Cancer Genomics and Proteomics
MedicineBiochemistryGeneticsMolecular BiologyCancer Research
2018English

TAS4464, a Highly Potent and Selective Inhibitor of NEDD8 Activating Enzyme, Suppresses Neddylation and Shows Antitumor Activity in Diverse Cancer Models

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

Unlucky Number 13? Differential Effects of KIT Exon 13 Mutation in Gastrointestinal Stromal Tumors

Molecular Oncology
Cancer ResearchMedicineOncologyGeneticsMolecular Medicine
2008English

Protein Kinase C-Θ Regulates KIT Expression and Proliferation in Gastrointestinal Stromal Tumors

Oncogene
Cancer ResearchGeneticsMolecular Biology
2008English

Gastrointestinal Stromal Tumors

Discussion of Clinical Cases
2015English

Concomitant KIT/BRAF and PDGFRA/BRAF Mutations Are Rare Events in Gastrointestinal Stromal Tumors

Oncotarget
Oncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy